QLQing Liu

Qing Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qing Liu has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Ying Zhang

    The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China

    5 shared publications
  • Qun Li

    The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China

    3 shared publications
  • Xin Wang

    The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China

    3 shared publications
  • Yan Liu

    The Department of Anesthesiology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, China

    3 shared publications
  • Yan-Qing Liu

    Department of Painology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    3 shared publications
  • Ying Zhang

    Department of Painology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China

    3 shared publications

Latest Publications

  • Open Access

    A Chinese Guideline for the Diagnosis and Management of Chronic Post-Traumatic Pain (2023 Edition)

    by Yan Lyu, Zhixiang Cheng, Xianguo Liu, Qing Liu, Jinfeng Liu, Xiaoqiu Yang, Suoliang Wang, Lin Wang, Zhigang Zhuang, Cunwei Shi, et al.

    With the rapid modernization of society, the incidence of traumatic events, including traffic accidents, industrial injuries, falls, and burn injuries has increased substantially, leading to a corresponding rise in the prevalence of chronic post-traumatic pain (CPTP). Chronic pain following trauma is predominantly neuropathic in nature, often involving central and peripheral sensitization mechanisms, and imposes a significant burden on patients' physical function, psychological well-being, sleep quality, and overall quality of life. Despite its growing clinical importance and socioeconomic impact, the diagnosis and management of CPTP remain insufficiently standardized across healthcare settings, with considerable variability in assessment tools, treatment protocols, and multidisciplinary coordination. To address this gap, the Expert Panel of the Special Capacity-Building Program for Pain Diagnosis and Treatment, organized by the National Health Commission Capacity Building and Continuing Education Center, systematically reviewed and critically appraised recent domestic and international evidence regarding the classification, prevention, diagnosis, and treatment of CPTP. High-quality evidence, including systematic reviews, meta-analyses, randomized controlled trials, clinical guidelines, and expert consensus statements, was evaluated using the GRADE methodology. Following repeated expert discussions and consensus voting, this guideline was developed to provide evidence-based, actionable recommendations for the standardized diagnosis and multidisciplinary management of CPTP. This guideline covers risk stratification, early intervention strategies, pharmacological and interventional therapies, psychological support, and rehabilitation approaches, with the ultimate aim of improving clinical practice consistency, enhancing patient outcomes, and reducing the long-term disability associated with chronic post-traumatic pain.

  • Top Cited Papers

    Gastrodin Ameliorates Pain-Depression Comorbidity through SIRT3-Dependent Alleviation of Oxidative Stress and Promotion of Mitochondrial Biogenesis

    by Feiran Zhou, Yijian Luo, Yan Liu, Lin Luo, Ping Jiang, Qing Liu, Ying Zhang

    Neuropathic pain (NP) and depression frequently co-occur, creating a complex clinical challenge with limited therapeutic options due to poorly understood shared mechanisms. Our preliminary screening identified the mitochondrial deacetylase SIRT3 as a potential key regulator of this comorbidity. Building on this finding, we hypothesized that Gastrodin, a natural compound with documented neuroprotective properties, exerts its therapeutic effects by targeting SIRT3. This study was therefore designed to investigate whether Gastrodin alleviates NP-depression comorbidity through a SIRT3-dependent mechanism. A rat model of NP-depression comorbidity was established by combining spared sciatic nerve injury (SNI) with chronic unpredictable mild stress (CUMS). Behavioral tests were conducted to assess mechanical allodynia, thermal hyperalgesia, and depression-like behaviors. Molecular mechanisms were evaluated using Western blot, ELISA, qPCR, and transmission electron microscopy. The specific role of SIRT3 was confirmed using the inhibitor 3-TYP in vivo and siRNA in vitro. Gastrodin administration (200/300 mg/kg) significantly ameliorated both pain hypersensitivity and depression-like behaviors in the comorbidity model. Mechanistically, Gastrodin upregulated SIRT3 expression and enhanced its deacetylase activity in the hippocampus, as evidenced by reduced acetylation of SOD2. This led to attenuated neuroinflammation (TNF-α, IL-1β, IL-6) and oxidative stress (MDA, ROS). Furthermore, Gastrodin improved mitochondrial ultrastructure and promoted mitochondrial biogenesis via the PGC-1α/TFAM pathway in astrocytes. Critically, all therapeutic benefits of Gastrodin were abolished upon SIRT3 inhibition. Gastrodin exerts dual therapeutic effects on NP-depression comorbidity by activating the SIRT3 pathway, thereby rescuing mitochondrial function in hippocampal astrocytes. These findings identify Gastrodin as a promising candidate for treating pain-depression comorbidity and underscore SIRT3 as a critical therapeutic target.


  • Open Access

    A Chinese Guideline for the Diagnosis and Treatment of Chronic LOW Back Pain (2024 Edition)

    by Zhi-Xiang Cheng, Xian-Guo Liu, Yan Lu, Ke Ma, Dong Huang, Qing Liu, Xiao-Qiu Yang, Li-Juan Lu, Tang-Hua Liu, Lin Wang, et al.

    Background: Low back pain (LBP) is the leading cause of disability worldwide, severely impairing patients' quality of life, consuming substantial healthcare resources, and increasing medical costs while reducing productivity. Low back pain has become the leading cause of disability worldwide and a major global public health issue. Objective: To enhance the ability of diagnosis and treatment for LBP to meet the needs of clinical diagnosis and treatment. Main ideas: Based on high quality evidence based medical research on the diagnosis and treatment of LBP published domestically and internationally between January 2010 and December 2023, the expert group of the Pain Disease Diagnosis and Treatment Special Capacity Enhancement Project of the National Health Commission of China's Capacity Building and Continuing Education Centerhas formed recommendations for common treatment methods through rigorous argumentation and expert voting, to provide references for standardized diagnosis and treatment of LBP. This guideline adopts GRADE methodology to evaluate the level of evidence and strength of recommendation for the treatments of common chronic specific low back pain (cSLBP) and chronic non-specific low back pain (cNSLBP). Conclusion: LBP is characterized by high prevalence, significant disability rates, and frequent recurrence, imposing substantial burdens on individuals, families, and society. For patients, improving understanding of cLBP, practicing effective self-management, and actively cooperating with treatment are crucial for disease prognosis. Healthcare providers must enhance patient education and clinical competencies while strictly adhering to diagnostic and therapeutic guidelines for comprehensive cLBP management. Policymakers and academic organizations should focus on developing evidence-based clinical guidelines, strengthening healthcare system oversight, and promoting widespread implementation of standardized cLBP care protocols.

  • Open Access

    Correction: Endoglin alleviates neuropathic pain by protecting the blood–spinal cord barrier through the TGF-β/Smad2 signaling pathway

    by SiJing Liao, Fei-Ran Zhou, Qun Li, Tao Jin, Gui-Fang Xiang, Xin Wang, Yan Liu, Hq Zhu, Qing Liu, Yuexin Liu, et al.

    A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval. Instructions: ● Please read through all the templates before choosing ● Pick the most relevant text template(s) from the following page and delete all others. ● Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. ● Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary ● Submit to Frontiers following the instructions on this page. When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example: There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake. The original version of this article has been updated. In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Correction: Endoglin alleviates neuropathic pain by protecting the blood–spinal cord barrier through the TGF-β/Smad2 signaling pathway Correction on: Liao S, Zhou F-R, Li Q, Jin T, Xiang G-F, Wang X, Liu Y, Zhu H, Liu Q, Liu Y and Zhang Y (2025) Endoglin alleviates neuropathic pain by protecting the blood–spinal cord barrier through the TGF-β/Smad2 signaling pathway. Front. Mol.Neurosci.18:1603619.doi:10.3389/fnmol.2025.1603619 Author affiliation Affiliation [1、Traditional Chinese Medicine Hospital of Meishan, Meishan, China 2、 The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China 3、Hejiang Traditional Chinese Medicine Hospital, Luzhou, China] was erroneously given as [1、Traditional Chinese Medicine Hospital of Meishan, Meisham, China 2、Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China 3、Hejiang County Traditional Chinese Medicine Hospital, Luzhou, China].. The original version of this article has been updated.

  • Open Access

    Endoglin alleviates neuropathic pain by protecting the blood–spinal cord barrier through the TGF-β/Smad2 signaling pathway

    by SiJing Liao, Fei-Ran Zhou, Qun Li, Tao Jin, Gui-Fang Xiang, Xin Wang, Yan Liu, Hq Zhu, Qing Liu, Yuexin Liu, et al.

    Introduction: Central neuroinflammation is pivotal in neuropathic pain pathogenesis, with blood-spinal cord barrier (BSCB) dysfunction recognized as a trigger for neuroinflammation and pain, though molecular mechanisms remain poorly understood.Methods: Through comparative clinical studies measuring serum endoglin in postherpetic neuralgia (PHN) patients versus healthy controls, and animal investigations using spared nerve injury (SNI) rat models with recombinant endoglin intervention, we assessed mechanical/thermal hyperalgesia, microglial activation, inflammatory cytokines, BSCB permeability, and TGF-βRI/Smad2/NR2B phosphorylation.Results: PHN patients exhibited lower serum endoglin versus controls; SNI rats showed reduced spinal endoglin compared to sham controls. Recombinant endoglin alleviated hyperalgesia while reversing microglial activation, inflammation, BSCB impairment, and NR2B phosphorylation. SNI decreased spinal TGF-βRI expression and Smad2 phosphorylation.Discussion: These findings demonstrate that endoglin reduction disrupts BSCB integrity via TGF-β/Smad2 pathway inhibition in endothelial cells, driving microglial activation, neuroinflammation, and NR2B phosphorylation, thereby elucidating a key pain mechanism and identifying endoglin as a therapeutic target.


  • Identification of hub genes in calcific aortic valve disease

    by Qian-Cheng Lai, Jie Zheng, Jian Mou, Chun-Yan Cui, Qing-Chen Wu, Syed M Musa Rizvi, Ying Zhang, Tian -Mei Li, Ying-Bo Ren, Qing Liu, et al.


  • Open Access

    Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma

    by Qinjuan Wu, Xin Li, Menghong Long, Xianfeng Xie, Qing Liu

    Histone lysine lactylation (Kla) plays a vital role in the tumorigenesis of hepatocellular carcinoma (HCC). Hence, we focused on Kla-specific genes to select novel therapeutic targets. Differentially expressed Kla-specific genes (DEKlaGs) were identified from TCGA with the cut-off criteria |log2(FlodChange (FC))| > 2, p-value < 0.05, following investigating the prognostic value. The correlation between lactate accumulation and prognostic DEKlaGs expression was further investigated. On the other hand, we explored the roles of Kla activation in the immune microenvironment, immunotherapy, and drug resistance. We conducted gene set enrichment analysis (GSEA) to predict the pathways influenced by Kla. The predictive power of Cox model was further identified in ICGC and GEO databases. A total of 129 DEKlaGs were identified, and 32 molecules might be potential prognostic biomarkers. A Cox model including ARHGEF37, MTFR2, NR6A1, NT5DC2, OSBP2, RNASEH2A, SFN, and UNC119B was constructed, which suggested unfavorable overall survival in high-risk score group, and risk score could serve as an indicator for large tumor size, poor pathological grade and advanced stage. NR6A1, OSBP2 and UNC119B could inhibit NK cell as well as TIL cell infiltration, and impair Type-I and II IFN responses in HCC, thereby contributing to unsatisfactory prognosis and immunotherapy resistance. OSBP2 and UNC119B were identified to be related to chemotherapy resistance. GSEA showed that WNT, MTOR, MAPK and NOTCH signaling pathways were activated, indicating that these pathways might play a crucial role during the Kla process. On the other hand, we showed that NR6A1 and OSBP2 were overexpressed in GEO. OSBP2 and UNC119B contributed to poor survival and advanced stage in ICGC. In summary, histone Kla was related to HCC prognosis and might serve as an independent biomarker. NR6A1, OSBP2 and UNC119B were associated with the prognosis, immunotherapy, and chemotherapy resistance, suggesting that NR6A1, OSBP2 and UNC119B might be novel candidate therapeutic targets for HCC.


  • Open Access

    Identification of key candidate genes and biological pathways in neuropathic pain

    by Chun-Yan Cui, Xiao Liu, Ming-Hui Peng, Qing Liu, Ying Zhang


  • Open Access

    Identification of perioperative neurocognitive dysfunction biomarkers in cerebrospinal fluid with quantitative proteomic approach in patients undergoing transurethral resection of prostate with combined spinal and epidural analgesia

    by Tian-Yan Bs Luo, Wei Bs Zhou, Gui-Fang Bs Xiang, Ying Zhang, Qing Liu

    Background: This study aimed to identify predictive biomarkers of perioperative neurocognitive dysfunction (PND) in cerebrospinal fluid of elderly male patients undergoing elective transurethral resection of prostate, using an isobaric tags for relative and absolute quantitative-based quantitative proteomic approach. Methods: Patients were evaluated with Mini Mental State Examination at −1 and+3 days of operation. Presence of PND was determined with Z-score method. Patients characteristics and quantitative cerebrospinal fluid proteomes detected with isobaric tags for relative and absolute quantitative-were compared between PND and non-PND patients. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis were performed to identify pathways potentially involved in PND. Result: A total of 229 patients were included in the study and 32 were diagnosed with PND (incidence 14.4%). The age, incidence of hypertension, and diabetes of PND patients were significantly higher than non-PND patients (P < .05). There were 85 differentially expressed proteins identified, among which High Mobility Group Box 1, prostaglandin D synthase, and matrix metalloproteinase inhibitor were considered to be promising candidates as they might play important roles in pathophysiology of PND. Conclusion: Proteomic approach identified potential biomarkers for predicting the occurrence of PND. These findings need to be validated in further studies.